Stockscreener 앱 받기
5.65
6.92%
-0.42
시간 외 거래:
5.66
0.010
+0.18%
전일 마감가:
$6.07
열려 있는:
$6
하루 거래량:
190.55K
Relative Volume:
0.94
시가총액:
$48.99M
수익:
$137.27M
순이익/손실:
$-123.57M
주가수익비율:
-0.5129
EPS:
-11.016
순현금흐름:
$-102.89M
1주 성능:
-10.74%
1개월 성능:
-11.44%
6개월 성능:
-23.23%
1년 성능:
-59.63%
1일 변동 폭
$5.41
$6.00
1주일 범위
$5.41
$6.40
52주 변동 폭
$3.51
$14.24
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
명칭
Karyopharm Therapeutics Inc
전화
617-658-0600
주소
85 WELLS AVENUE, NEWTON, MA
KPTI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
5.65 | 96.68M | 137.27M | -123.57M | -102.89M | -11.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-13 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-07-16 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | 재개 | H.C. Wainwright | Buy |
| 2023-01-19 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-11-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-08-06 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | 개시 | Morgan Stanley | Overweight |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-07-23 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-05 | 재확인 | Robert W. Baird | Outperform |
| 2019-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-02-28 | 재확인 | BofA/Merrill | Underperform |
| 2019-02-27 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | 개시 | B. Riley FBR | Buy |
| 2018-11-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2018-05-24 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-04-02 | 재개 | Leerink Partners | Outperform |
| 2017-11-15 | 재개 | H.C. Wainwright | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2016-09-08 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-08-18 | 개시 | H.C. Wainwright | Buy |
| 2016-06-28 | 개시 | Robert W. Baird | Outperform |
모두보기
Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스
KPTI: RBC Capital Lowers Price Target While Maintaining Outperfo - GuruFocus
Karyopharm Therapeutics (NASDAQ:KPTI) Issues Quarterly Earnings Results - MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2025 Earnings Call Transcript - Insider Monkey
RBC Cuts Price Target on Karyopharm Therapeutics to $19 From $30, Keeps Outperform Rating - MarketScreener
What makes Karyopharm Therapeutics Inc. (25K0) stock appealing to growth investorsPortfolio Risk Summary & Long-Term Growth Plans - newser.com
Quantitative breakdown of Karyopharm Therapeutics Inc. recent moveQuarterly Performance Summary & Low Risk High Win Rate Stock Picks - newser.com
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
How Karyopharm Therapeutics Inc. stock compares to industry benchmarksWeekly Trend Summary & Weekly High Return Stock Opportunities - newser.com
Karyopharm Therapeutics: Q3 Earnings Snapshot - New Haven Register
Karyopharm Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat
Karyopharm Therapeutics Reports Q3 2025 Financial Results - TipRanks
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Down 36.3% in October - MarketBeat
Karyopharm Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Karyopharm (Nasdaq: KPTI) grants 800 RSUs to new hire, vesting over 3 years - Stock Titan
Karyopharm (KPTI) Reports Strong Q3 2025, Highlights Myelofibros - GuruFocus
Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full Year 2025 - MarketScreener
Transcript : Karyopharm Therapeutics Inc., Q3 2025 Earnings Call, Nov 03, 2025 - MarketScreener
Karyopharm Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Earnings call transcript: Karyopharm Q3 2025 shows revenue growth, pre-market dip - Investing.com
How geopolitical tensions affect Karyopharm Therapeutics Inc. stock2025 Historical Comparison & Free Expert Approved Momentum Trade Ideas - newser.com
Karyopharm Grows Revenue With Strong XPOVIO Sales And Partnerships - Finimize
Is Karyopharm Therapeutics Inc. (25K0) stock a top hedge fund pickIPO Watch & Safe Capital Growth Trade Ideas - newser.com
Analyzing net buyer seller activity in Karyopharm Therapeutics Inc.July 2025 Final Week & High Accuracy Trade Signal Alerts - newser.com
Karyopharm (KPTI) Surpasses Q3 Revenue Expectations with Clinica - GuruFocus
Karyopharm (KPTI) Projects Revenue Growth and Expense Reduction for FY25 - GuruFocus
Is Karyopharm Therapeutics Inc. stock safe for conservative investorsQuarterly Trade Summary & Verified Short-Term Plans - newser.com
Karyopharm Therapeutics Inc. SEC 10-Q Report - TradingView
Karyopharm Therapeutics' Q3 net loss widens - TradingView
Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress - PR Newswire
Will Karyopharm Therapeutics Inc. stock gain from strong economyQuarterly Portfolio Summary & Community Consensus Trade Signals - newser.com
How Karyopharm Therapeutics Inc. (25K0) stock reacts to new regulationsQuarterly Market Review & Verified Technical Trade Signals - newser.com
Karyopharm Therapeutics Inc. stock trend outlook and recovery path2025 Major Catalysts & Weekly Chart Analysis and Trade Guides - newser.com
Is it time to cut losses on Karyopharm Therapeutics Inc.July 2025 EndofMonth & Weekly Setup with High ROI Potential - newser.com
Using Ichimoku Cloud for Karyopharm Therapeutics Inc. technicalsPortfolio Risk Summary & Low Drawdown Trading Techniques - newser.com
Will Karyopharm Therapeutics Inc. outperform the marketM&A Rumor & Safe Entry Trade Reports - newser.com
Technical signs of recovery in Karyopharm Therapeutics Inc.July 2025 Technicals & Verified Momentum Stock Watchlist - newser.com
Is Karyopharm Therapeutics Inc. (25K0) stock cheap vs fundamentalsMarket Performance Summary & Fast Entry High Yield Stock Tips - newser.com
Will Karyopharm Therapeutics Inc. stock benefit from AI adoptionJuly 2025 Drop Watch & Growth Focused Stock Reports - newser.com
Can Karyopharm Therapeutics Inc. stock continue upward trendChart Signals & Fast Exit and Entry Trade Guides - newser.com
Is Karyopharm Therapeutics Inc. stock vulnerable to regulatory risksWeekly Earnings Recap & Weekly Return Optimization Alerts - newser.com
Karyopharm Therapeutics Inc (KPTI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):